FierceBiotech 6 ene 2026 FDA cites severe liver injury risk, unclear benefit behind Sanofi's MS drug rejection
FierceBiotech 6 ene 2026 UK biotech eyes $1B deal to enable eye gene therapy to be delivered in doctors' offices
FierceBiotech 5 ene 2026 Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
FierceBiotech 5 ene 2026 Abbott launches AI-based Libre Assist, its new in-app feature for meal planning
FierceBiotech 5 ene 2026 Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier
FierceBiotech 2 ene 2026 Cellular energy booster restores cognition in mice with advanced Alzheimer’s disease
FierceBiotech 2 ene 2026 NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership
FierceBiotech 2 ene 2026 Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs
FierceBiotech 2 ene 2026 Neuralink to kick-start 'high-volume production' of brain-computer interface devices, Elon Musk says
FierceBiotech 2 ene 2026 Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease